BACKGROUND: Infection is the most important cause of treatment-related morbidity and mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although routine in adults with leukemia, antibacterial prophylaxis is controversial in pediatrics because of insufficient evidence for its efficacy or antibiotic choice and concerns about promoting antibiotic resistance and Clostridium difficile infection. METHODS: This was a single-center, observational cohort study of patients with newly diagnosed ALL, comparing prospectively collected infection-related outcomes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during induction therapy on the total XVI study. A propensity score-weighted logistic regression model was used to adjust for confounders. RESULTS: Of 344 included patients, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophylaxis regimens. Patients receiving prophylaxis had longer duration of neutropenia. Prophylaxis reduced the odds of febrile neutropenia, likely bacterial infection, and bloodstream infection by ≥70%. Levofloxacin prophylaxis alone reduced these infections, but it also reduced cephalosporin, aminoglycoside, and vancomycin exposure and reduced the odds of C. difficile infection by >95%. No increase in breakthrough infections with antibiotic-resistant organisms was seen, but this cannot be excluded. CONCLUSIONS: This is the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a broad-spectrum fluoroquinolone. Prophylaxis prevented febrile neutropenia and systemic infection. Levofloxacin prophylaxis also minimized the use of treatment antibiotics and drastically reduced C. difficile infection. Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL. CLINICAL TRIALS REGISTRATION: NCT00549848.
BACKGROUND: Infection is the most important cause of treatment-related morbidity and mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although routine in adults with leukemia, antibacterial prophylaxis is controversial in pediatrics because of insufficient evidence for its efficacy or antibiotic choice and concerns about promoting antibiotic resistance and Clostridium difficile infection. METHODS: This was a single-center, observational cohort study of patients with newly diagnosed ALL, comparing prospectively collected infection-related outcomes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during induction therapy on the total XVI study. A propensity score-weighted logistic regression model was used to adjust for confounders. RESULTS: Of 344 included patients, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophylaxis regimens. Patients receiving prophylaxis had longer duration of neutropenia. Prophylaxis reduced the odds of febrile neutropenia, likely bacterial infection, and bloodstream infection by ≥70%. Levofloxacin prophylaxis alone reduced these infections, but it also reduced cephalosporin, aminoglycoside, and vancomycin exposure and reduced the odds of C. difficile infection by >95%. No increase in breakthrough infections with antibiotic-resistant organisms was seen, but this cannot be excluded. CONCLUSIONS: This is the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a broad-spectrum fluoroquinolone. Prophylaxis prevented febrile neutropenia and systemic infection. Levofloxacin prophylaxis also minimized the use of treatment antibiotics and drastically reduced C. difficile infection. Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL. CLINICAL TRIALS REGISTRATION: NCT00549848.
Authors: M E Santolaya; A M Alvarez; A Becker; J Cofré; N Enríquez; M O'Ryan; E Payá; J Pilorget; C Salgado; J Tordecilla; M Varas; M Villarroel; T Viviani; M Zubieta Journal: J Clin Oncol Date: 2001-07-15 Impact factor: 44.544
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer Journal: Nature Date: 2014-10-22 Impact factor: 49.962
Authors: Hana Hakim; Ronald Dallas; Joshua Wolf; Li Tang; Stacey Schultz-Cherry; Victoria Darling; Cydney Johnson; Erik A Karlsson; Ti-Cheng Chang; Sima Jeha; Ching-Hon Pui; Yilun Sun; Stanley Pounds; Randall T Hayden; Elaine Tuomanen; Jason W Rosch Journal: Clin Infect Dis Date: 2018-08-01 Impact factor: 9.079
Authors: Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling Journal: Pediatr Blood Cancer Date: 2019-02-13 Impact factor: 3.167
Authors: Seth E Karol; Thomas B Alexander; Amit Budhraja; Stanley B Pounds; Kristin Canavera; Lei Wang; Joshua Wolf; Jeffery M Klco; Paul E Mead; Soumyasri Das Gupta; Su Y Kim; Ahmed Hamed Salem; Tammy Palenski; Norman J Lacayo; Ching-Hon Pui; Joseph T Opferman; Jeffrey E Rubnitz Journal: Lancet Oncol Date: 2020-03-11 Impact factor: 41.316
Authors: Sarah Alexander; Brian T Fisher; Aditya H Gaur; Christopher C Dvorak; Doojduen Villa Luna; Ha Dang; Lu Chen; Michael Green; Michael L Nieder; Beth Fisher; L Charles Bailey; John Wiernikowski; Lillian Sung Journal: JAMA Date: 2018-09-11 Impact factor: 56.272
Authors: Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller Journal: Leuk Lymphoma Date: 2020-12-01
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19
Authors: Thomas Lehrnbecher; Brian T Fisher; Bob Phillips; Sarah Alexander; Roland A Ammann; Melissa Beauchemin; Fabianne Carlesse; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Grace Egan; Andreas H Groll; Gabrielle M Haeusler; Maria Santolaya; William J Steinbach; Marianne van de Wetering; Joshua Wolf; Sandra Cabral; Paula D Robinson; Lillian Sung Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079